Beam Therapeutics Inc (NASDAQ: BEAM) has experienced a decline in its stock price by -2.02 compared to its previous closing price of 26.04. However, the company has seen a fall of -2.98% in its stock price over the last five trading days. zacks.com reported 2024-09-05 that Beam Therapeutics (BEAM) reported earnings 30 days ago. What’s next for the stock?
Is It Worth Investing in Beam Therapeutics Inc (NASDAQ: BEAM) Right Now?
Company’s 36-month beta value is 1.85.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 7 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BEAM is 71.60M, and currently, short sellers hold a 15.48% ratio of that floaft. The average trading volume of BEAM on September 20, 2024 was 1.07M shares.
BEAM’s Market Performance
BEAM’s stock has seen a -2.98% decrease for the week, with a 0.10% rise in the past month and a 11.23% gain in the past quarter. The volatility ratio for the week is 5.54%, and the volatility levels for the past 30 days are at 5.46% for Beam Therapeutics Inc The simple moving average for the past 20 days is 1.07% for BEAM’s stock, with a -6.63% simple moving average for the past 200 days.
Analysts’ Opinion of BEAM
Many brokerage firms have already submitted their reports for BEAM stocks, with H.C. Wainwright repeating the rating for BEAM by listing it as a “Buy.” The predicted price for BEAM in the upcoming period, according to H.C. Wainwright is $80 based on the research report published on July 23, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see BEAM reach a price target of $40, previously predicting the price at $38. The rating they have provided for BEAM stocks is “Overweight” according to the report published on January 29th, 2024.
BofA Securities gave a rating of “Neutral” to BEAM, setting the target price at $35 in the report published on December 15th of the previous year.
BEAM Trading at -3.01% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.45% of loss for the given period.
Volatility was left at 5.46%, however, over the last 30 days, the volatility rate increased by 5.54%, as shares surge +4.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.12% lower at present.
During the last 5 trading sessions, BEAM fell by -2.70%, which changed the moving average for the period of 200-days by -13.43% in comparison to the 20-day moving average, which settled at $25.30. In addition, Beam Therapeutics Inc saw -6.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Simon Amy, who sale 748 shares at the price of $22.95 back on Jul 02 ’24. After this action, Simon Amy now owns 68,805 shares of Beam Therapeutics Inc, valued at $17,167 using the latest closing price.
Simon Amy, the Chief Medical Officer of Beam Therapeutics Inc, sale 502 shares at $23.76 during a trade that took place back on Jul 01 ’24, which means that Simon Amy is holding 69,553 shares at $11,928 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -0.52 for the present operating margin
- 0.93 for the gross margin
The net margin for Beam Therapeutics Inc stands at -0.41. The total capital return value is set at -0.17. Equity return is now at value -17.17, with -10.94 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -0.83. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is -4.73.
Currently, EBITDA for the company is -156.47 million with net debt to EBITDA at 0.76. When we switch over and look at the enterprise to sales, we see a ratio of 5.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.81.
Conclusion
In a nutshell, Beam Therapeutics Inc (BEAM) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
